Navigation Links
Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
Date:8/13/2008

this financing," remarked President and CEO Paul F. Truex of Anthera Pharmaceuticals, Inc. "This investment and the ongoing support of our existing investors including VantagePoint and Sofinnova are a clear acknowledgement of our accomplishments and the potential of our product pipeline."

"We are excited about Anthera and its late-stage anti-inflammatory platform. We believe the company's lead candidate, Varespladib, has demonstrated synergy with statins and represents a potential breakthrough treatment for people at risk for cardiovascular disease," said Rachel Leheny, Ph.D., Managing Director of Caxton Advantage Venture Partners. "We believe Varespladib's unique mechanism of action will lead to improved patient outcomes and we look forward to its continued development."

In two previous clinical trials, Varespladib, a potent inhibitor of secretory phospholipase A2 (sPLA2), has demonstrated marked improvements in independent markers of cardiovascular risk including a near complete suppression of the target enzyme, a clinically meaningful and statistically significant reduction in cholesterol, and a reduction in C-reactive protein.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co.‚ Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes‚ prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel‚ upstream steps in the inflammation cascade and have the potential to addres
'/>"/>

SOURCE Anthera Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Anthera Pharmaceuticals Forms Scientific Advisory Board
3. Anthera Presents Data on Varespladib at ATVB Meeting
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... LA JOLLA, Calif., Jan. 17, 2012  Synthetic Genomics Inc. ... solutions to solve a wide range of global challenges, ... Vice President for Nutritional Products. Stagnitti is a proven ... translating these into high value food and nutritional products ...
... Jan. 17, 2012 Reliv International, Inc. (NASDAQ: ... of LunaRich™, an exclusive soy powder developed at the Missouri ... of its nutritional supplements and will reveal that product at ... "Biotechnology is vital to Missouri,s economic future," said ...
... Inc. (NASDAQ: VVUS ) today announced that ... The Journal of Sexual Medicine (JSM), a peer-reviewed ... randomized, placebo-controlled, phase 3 study evaluating the safety and ... by the Food and Drug Administration (FDA) for the ...
Cached Biology Technology:Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program 2Reliv and Soy Labs Launch LunaRich, a Healthier Soy 2Reliv and Soy Labs Launch LunaRich, a Healthier Soy 3Reliv and Soy Labs Launch LunaRich, a Healthier Soy 4REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 2REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 3REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 4REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 5REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 6
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... aimed at preventing cervical cancer is nearly 100 percent effective ... for most cases of cervical cancer. Results of a nationwide ... 9 issue of the New England Journal of Medicine. , ... deaths in women worldwide, resulting in nearly half a million ...
... helping to build a compelling case for oncolytic ... many cancers. , Reovirus, a non-pathogenic ... has shown powerful anti-cancer activity against cultured tumor ... trials. Oncolytics' proprietary reovirus formulation, Reolysin®, is active ...
... Universitat Autònoma de Barcelona, in cooperation with the animal ... model which faithfully reproduces the characteristics of dog’s skin ... various lines of research related to skin biology and ... The basic structure of skin consists of an external ...
Cached Biology News:Study shows continued success for new HPV vaccine against virus responsible for cervical cancer 2Dealing deadly cancers a knockout punch 2Dealing deadly cancers a knockout punch 3
Human M-CSF...
Human Serpin B5/Maspin Affinity Purified Polyclonal Ab...
... and S.J. Allen (1995) This ... world authorities on current issues relating to ... Several major advances have been made recently ... disease. Topics include molecular neuropathology through clinical ...
Normal human serum, single donor...
Biology Products: